Table 2 Comparison of clinical data among the three groups
Psoriasis with depression | Psoriasis without depression | The control group | Z、F或χ2 | P | |
|---|---|---|---|---|---|
Number，n | 18 | 72 | 40 | ||
Dopamine (pg/ml) | 50.15(47.01-51.43) | 54.74(51.54-57.93) | 57.08(52.78-63.11) | 7.359 | 0.001 |
Phenylephrine (pg/ml) | 29.84 (29.12-31.53) | 31.78(29.17-34.30) | 36.77(29.79-41.18) | 1.190 | 0.308 |
Norepinephrine (pg/ml) | 149.22(140.05-158.83) | 149.28(142.99-161.13) | 154.52(142.51-163.88) | 0.704 | 0.497 |
Age (year) | 48(44-67) | 41(24-52) | 44(31-50) | 6.002 | 0.003 |
Sex (male),n(%) | 13(72) | 54(75) | 26(65) | 1.268 | 0.531 |
Poor economic condition, n(%) | 6(33) | 15(21) | 4(10) | 4.672 | 0.097 |
Course of disease (month) | 120(45-240) | 72(6-120) | -2.226 | 0.026 | |
PASI score | 39(31-49) | 29(18-37) | -2.542 | 0.011 | |
DLQI score | 11(10-17) | 4(2-7) | -6.152 | 0.000 | |
Family history, n(%) | 6(33%) | 9(13) | 4.500 | 0.034 | |
The number of insomnia, n(%) | 11(61) | 12(17) | 3(7.5) | 23.420 | 0.000 |